Pharmacokinetic evaluation of tapentadol extended-release tablets in healthy subjects
DOI:
https://doi.org/10.5055/jom.2013.0171Keywords:
tapentadol, extended release, pharmacokineticsAbstract
Objective: To evaluate serum pharmacokinetics of tapentadol administered to healthy subjects as extended-release (ER) tablets.
Design: Seven single-dose studies (five randomized, crossover, bioequivalence studies; a study in Japanese men; and a randomized, crossover, effects-of-food study) and one repeated-dose study.
Setting: Clinical research settings in the United States and The Netherlands.
Patients or participants: Healthy males and females were enrolled into seven studies; one study enrolled only Japanese males.
Interventions: In the bioequivalence studies, subjects first received one polyethylene oxide- or hypromellose-based tapentadol ER tablet (50, 100, 150, 200, or 250 mg; one dose per study), then (after washout) the other formulation (matching dose). In all other studies, subjects received polyethylene oxide-based tapentadol ER tablets. In the repeated-dose study, subjects received one 250 mg tablet, then (after washout) one 250 mg tablet every 12 hours (five doses). In the food-effect study, subjects received one 250 mg tablet within 30 minutes after a high-fat meal or after 10 hours of fasting. In the study in Japanese men, subjects received one 100 mg tablet.
Main outcome measures: Maximum tapentadol concentrations (Cmax) were typically observed 5 hours after dosing. Mean terminal half-life values ranged from 4.4 to 5.9 hours. Tapentadol Cmax and AUC values increased proportionally following single ER (polyethylene oxide-based tablets) doses of 50 to 250 mg. Trough tapentadol concentrations increased during repeat dosing until reaching steady-state by the third dose. Serum Cmax and area under the concentration-time curve (AUC) values at steady state were 1.6 and 1.9 times higher relative to singledose administration. Coadministration of the 250 mg dose with a high-fat meal increased Cmax and AUC values by an average of <17 percent.
Conclusions: The pharmacokinetics of tapentadol ER are consistent after repeated and single-dose administration. Tapentadol ER may be administered without regard to food intake. No clinically significant differences were observed in the pharmacokinetics of tapentadol between Japanese and Caucasian subjects.
References
Tzschentke TM, Christoph T, Kögel B, et al.: (_)-(1R,2R)-3-(3-Dimethylamino-1-ethyl-2-methyl-propyl)-phenol hydrochloride (tapentadol HCl): A novel _—opioid receptor agonist/norepinephrine reuptake inhibitor with broad-spectrum analgesic properties. J Pharmacol Exp Ther. 2007; 323(1): 265-276.
Tzschentke TM, De Vry J, Terlinden R, et al.: Tapentadol hydrochloride. Analgesic, mu-opioid receptor agonist, noradrenaline reuptake inhibitor. Drugs Future. 2006; 31(12): 1053-1061.
Hartrick C, Van Hove I, Stegmann J-U, et al.: Efficacy and tolerability of tapentadol immediate release and oxycodone HCl immediate release in patients awaiting primary joint replacement surgery for end-stage joint disease: A 10-day, phase III, randomized, double-blind, active- and placebo-controlled study. Clin Ther. 2009; 31(2): 260-271.
Buynak R, Shapiro DY, Okamoto A, et al.: Efficacy and safety of tapentadol extended release for the management of chronic low back pain: Results of a prospective, randomized, double-blind, placebo- and active-controlled Phase III study. Expert Opin Pharmacother. 2010; 11(11): 1787-1804.
Afilalo M, Etropolski MS, Kuperwasser B, et al.: Efficacy and safety of tapentadol extended release compared with oxycodone controlled release for the management of moderate to severe chronic pain related to osteoarthritis of the knee: A randomized, double-blind, placebo- and active-controlled phase III study. Clin Drug Investig. 2010; 30(8): 489-505.
Etropolski M, Okamoto A, Shapiro DY, et al.: Dose conversion between tapentadol immediate and extended release for low back pain. Pain Physician. 2010; 13(1): 61-70.
Lange B, Kuperwasser B, Okamoto A, et al.: Efficacy and safety of tapentadol prolonged release for chronic osteoarthritis pain and low back pain. Adv Ther. 2010; 27(6): 381-399.
Schwartz S, Etropolski M, Shapiro DY, et al.: Safety and efficacy of tapentadol ER in patients with painful diabetic peripheral neuropathy: Results of a randomized-withdrawal, placebo-controlled trial. Curr Med Res Opin. 2011; 27(1): 151-162.
Wild JE, Grond S, Kuperwasser B, et al.: Long-term safety and tolerability of tapentadol extended release for the management of chronic low back pain or osteoarthritis pain. Pain Pract. 2010; 10(5): 416-427.
Janssen Pharmaceuticals: Nucynta® ER (tapentadol) extended-release oral tablets C-II [package insert]. Raritan, NJ: Janssen Pharmaceuticals, Inc., 2011.
Grunenthal: Palexia® SR (tapentadol) prolonged-release oral tablets [summary of product characteristics]. Buckinghamshire, UK: Grunenthal Ltd., 2011.
Vosburg SK, Jones JD, Manubay JM, et al.: Assessment of the ease with which prescription opioid abusers prepare a TRF versus a non-TRF for abuse. Presented at: the 73rd Annual Scientific Meeting of The College on Problems of Drug Dependence (CPDD). Hollywood, FL. June 18-23, 2011: 189, Abstract 753.
Janssen: NUCYNTA® CR tapentadol controlled-release tablets [package insert]. Markham, Ontario, Canada: Janssen Inc., 2012.
The European Agency for the Evaluation of Medicinal Products (ed.): Note for Guidance on the Investigation of Bioavailability and Bioequivalence. London: The European Agency for the Evaluation of Medicinal Products, 2001.
Minister of Public Works and Government Services: Guidance for Industry: Conduct and Analysis of Bioavailability and Bioequivalence Studies–Part B: Oral Modified Release Formulations. Canada: Minister of Public Works and Government Services, 1996.
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, et al. (eds.): Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products–General Considerations. Rockville, MD: Center for Drug Evaluation and Research, 2003.
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research: Guidance for industry: Food-effect bioavailability and fed bioequivalence studies. Available at http://www.fda.gov/downloads/RegulatoryInformation/Guidances/UCM126833.pdf. Accessed October 27, 2011.
US Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, et al. (eds.): Guidance for Industry: Bioanalytical Method Validation. Rockville, MD: Center for Drug Evaluation and Research, 2001.
Smit JW, Oh C, Rengelshausen J, et al.: Effects of acetaminophen, naproxen, and acetylsalicylic acid on tapentadol pharmacokinetics: Results of two randomized, open-label, crossover, drug-drug interaction studies. Pharmacotherapy. 2010; 30(1): 25-34.
Ortho-McNeil-Janssen Pharmaceuticals: Nucynta® (tapentadol) immediate-release oral tablets [package insert]. Raritan, NJ: Ortho-McNeil-Janssen Pharmaceuticals, Inc., 2011.
Kneip C, Terlinden R, Beier H, et al.: Investigations into the drug-drug interaction potential of tapentadol in human liver microsomes and fresh human hepatocytes. Drug Metab Lett. 2008; 2(1): 67-75.
Terlinden R, Kögel BY, Englberger W, et al.: In vitro and in vivo characterization of tapentadol metabolites. Methods Find Exp Clin Pharmacol. 2010; 32(1): 31-38.
Xu XS, Smit JW, Lin R, et al.: Population pharmacokinetics of tapentadol immediate release (IR) in healthy subjects and patients with moderate or severe pain. Clin Pharmacokinet. 2010; 49(10): 671-682.
Custodio JM, Wu CY, Benet LZ: Predicting drug disposition, absorption/elimination/transporter interplay and the role of food on drug absorption. Adv Drug Deliv Rev. 2008; 60(6): 717-733.
Published
How to Cite
Issue
Section
License
Copyright 2005-2024, Weston Medical Publishing, LLC
All Rights Reserved
